| 1.27 0.05 (4.1%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.01 |
1-year : | 2.45 |
| Resists | First : | 1.72 |
Second : | 2.09 |
| Pivot price | 1.48  |
|||
| Supports | First : | 1.12 |
Second : | 0.93 |
| MAs | MA(5) : | 1.26 |
MA(20) : | 1.54 |
| MA(100) : | 1.13 |
MA(250) : | 1.76 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 15.4 |
D(3) : | 12 |
| RSI | RSI(14): 43 |
|||
| 52-week | High : | 5.15 | Low : | 0.77 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RMTI ] has closed above bottom band by 22.6%. Bollinger Bands are 95.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.29 - 1.3 | 1.3 - 1.31 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.26 - 1.27 | 1.27 - 1.28 |
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Wed, 17 Sep 2025
Rockwell Medical, Inc. (NASDAQ:RMTI) Short Interest Update - MarketBeat
Tue, 02 Sep 2025
Rockwell Medical Surprises with Strong Cash Flow - StocksToTrade
Thu, 28 Aug 2025
There's No Escaping Rockwell Medical, Inc.'s (NASDAQ:RMTI) Muted Revenues Despite A 43% Share Price Rise - simplywall.st
Mon, 25 Aug 2025
Fast-paced Momentum Stock Rockwell Medical (RMTI) Is Still Trading at a Bargain - Yahoo Finance
Tue, 19 Aug 2025
Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Could Be 34% Below Their Intrinsic Value Estimate - simplywall.st
Thu, 14 Aug 2025
ROCKWELL MEDICAL Earnings Results: $RMTI Reports Quarterly Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 34 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 13.7 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 1,020 (K) |
| Shares Short P.Month | 102 (K) |
| EPS | -0.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | -2.4 % |
| Operating Margin | -8.4 % |
| Return on Assets (ttm) | -1.6 % |
| Return on Equity (ttm) | -7.8 % |
| Qtrly Rev. Growth | -37.8 % |
| Gross Profit (p.s.) | 0.44 |
| Sales Per Share | 2.55 |
| EBITDA (p.s.) | 0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -18.15 |
| PEG Ratio | 0 |
| Price to Book value | 1.44 |
| Price to Sales | 0.49 |
| Price to Cash Flow | 12.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|